Scientific article
English

IL-1 pathways in inflammation and human diseases

Published in

Nature reviews. Rheumatology, vol. 6, no. 4, p. 232-241

Publication date

2010

Abstract

Interleukin (IL)-1 was first cloned in the 1980s, and rapidly emerged as a key player in the regulation of inflammatory processes. The term IL-1 refers to two cytokines, IL-1alpha and IL-1beta, which are encoded by two separate genes. The effects of IL-1 are tightly controlled by several naturally occurring inhibitors, such as IL-1 receptor antagonist (IL-1Ra), IL-1 receptor type II (IL-1RII), and other soluble receptors. Numerous IL-1 inhibitors have been developed and tested primarily in rheumatoid arthritis, with only modest effects. By contrast, the use of IL-1 antagonists has been uniformly associated with beneficial effects in patients with hereditary autoinflammatory conditions associated with excessive IL-1 signaling, such as cryopyrinopathies and IL-1Ra deficiency. Successful treatment with IL-1 blockers has also been reported in other hereditary autoinflammatory diseases, as well as in nonhereditary inflammatory diseases, such as Schnizler syndrome, systemic-onset juvenile idiopathic arthritis and adult Still disease. The role of microcrystals in the regulation of IL-1beta processing and release has provided the rationale for the use of IL-1 inhibitors in crystal-induced arthritis. Finally, preliminary results indicating that IL-1 targeting is efficacious in type 2 diabetes and smoldering myeloma have further broadened the spectrum of IL-1-driven diseases.

Keywords

  • Animals
  • Cohort Studies
  • Disease Models, Animal
  • Drug Delivery Systems
  • Female
  • Humans
  • Inflammation/blood/physiopathology
  • Inflammation Mediators/blood
  • Interleukin 1 Receptor Antagonist Protein/therapeutic use
  • Interleukin-1/antagonists & inhibitors/metabolism
  • Interleukin-1beta/drug effects/metabolism
  • Male
  • Mice
  • Prognosis
  • Receptors, Interleukin/antagonists & inhibitors/drug effects
  • Rheumatic Diseases/blood/diagnosis/drug therapy
  • Risk Assessment
  • Signal Transduction
  • Treatment Outcome

Citation (ISO format)

GABAY, Cem, LAMACCHIA, Céline, PALMER-LOURENCO, Gaby. IL-1 pathways in inflammation and human diseases. In: Nature reviews. Rheumatology, 2010, vol. 6, n° 4, p. 232–241. doi: 10.1038/nrrheum.2010.4

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1759-4790
759views
1downloads

Technical informations

Creation

23/05/2012 08:45:35

First validation

23/05/2012 08:45:35

Update

13/02/2026 14:29:33

Status update

13/02/2026 14:29:33

Last indexation

13/02/2026 14:29:34
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated